Click a keyword to view all the abstracts on this site tagged with that keyword.
- Physical examination and ultrasound
- physical examination and x-ray
- physical function
- physical function and patient-reported outcome measures
- physical function and physical impairment
- physical function and physical therapy
- physical function and primary care
- physical function and prognostic factors
- Physical function and psoriatic arthritis
- physical function and quality of life
- physical function and rheumatoid arthritis
- physical function and rheumatoid arthritis (RA)
- physical function and socioeconomic status
- physical function and stress
- physical function and systemic lupus erythematosus (SLE)
- physical function and test
- physical function and total joint replacement
- physical impairment
- physical impairment and performance
- physical impairment and population studies
- physical impairment and psoriatic arthritis
- physical impairment and psychometric properties
- physical impairment and quality of life
- physical impairment and rheumatoid arthritis
- physical impairment and rheumatoid arthritis (RA)
- physical impairment and systemic lupus erythematosus (SLE)
- physical inactivity
- physical therapy
- physical therapy and physical activity
- physical therapy and pilot study
- physical therapy and population studies
- physical therapy and qualitative
- physical therapy and quality of life
- physical therapy and randomized trials
- physical therapy and rehabilitation
- physical therapy and rheumatoid arthritis (RA)
- physical therapy and self-management
- physical therapy and shoulder disorders
- physical therapy and spondylarthropathy
- physical therapy and surgery
- physical therapy and systemic sclerosis
- physical therapy and tai chi
- physical therapy and technology
- physical therapy and total joint replacement
- Physician Assistant
- Physician Assistant and nurse practitioners
- physician data
- physician data and psoriatic arthritis
- physician data and questionnaires
- physician data and remission
- physician data and rheumatoid arthritis (RA)
- physician data and rheumatologic practice
- physician data and risk
- physician data and systemic lupus erythematosus (SLE)
- physician data and trend
- physician data and women's health
- Physician Global Assesment
- Physician-Patient Interaction
- physiotherapy
- picu
- pilocarpine and treatment
- pilot study
- pilot study and spondylarthropathy
- pilot study and vasculitis
- PIMS
- pivotal and phase 3
- PKPD modeling
- placebo
- placenta
- placenta and pregnancy
- Plain Film
- Plaque Psoriasis and Psoriatic Arthritis
- plasma cells
- plasma cells and iga
- plasma cells and proteinuria
- plasma cells and rheumatoid arthritis
- plasma cells and rheumatoid arthritis (RA)
- plasma cells and scleroderma
- plasma cells and signal transduction
- plasma cells and systemic lupus erythematosus (SLE)
- plasma cells and therapeutic targeting
- plasma cells and tolerance
- plasma cells and toll-like receptors
- Plasmablasts
- Plasmablasts and antibodies
- Plasmablasts and biomarkers
- Plasmablasts and clinical trials
- Plasmablasts and rheumatoid arthritis (RA)
- Plasmablasts and SLE
- Plasmablasts and tertiary
- Plasmablasts and vasculitis
- Plasmablasts and Wegener's granulomatosis
- plasmacytoid dendritic cells and Type I IFN
- Plasticity
- platelets
- platelets and Pathophysiology
- platelets and rheumatoid arthritis
- platelets and rheumatoid arthritis (RA)
- platelets and scleroderma
- platelets and systemic lupus erythematosus (SLE)
- platelets and systemic sclerosis
- platelets and thrombosis
- platelets and toll-like receptors
- platelets and vasculitis
- Pneumococcal
- pneumococcal vaccine
- pneumocystis and opportunistic infections
- pneumonia
- Point-of-Care
- polyangiitis
- Polyangiitis and pulmonary complications
- Polyangiitis and pulmonary fibrosis
- polyangiitis and rituximab
- polyangiitis and vasculitis
- Polyarteritis nodosa
- polyarteritis nodosa and treatment options
- polyarteritis nodosa and vasculitis
- polyarthritis
- polyarthritis and prognostic factors
- polyarthritis and psoriatic arthritis
- polyarthritis and remission
- polyarthritis and rheumatoid arthritis (RA)
- polyarthritis and treatment
- Polyarthritis and viruses
- Polychondritis
- polychondritis and positron emission tomography (PET)
- polychondritis and regulatory cells
- polychondritis and statistical methods
- polychondritis and therapy
- polychondritis and tocilizumab
- polychondritis and transcription factor
- polychondritis and treatment
- polychondritis and ultrasonography
- polychondritis and vasculitis
- polyfunctional T cells
- Polyhedraloligomericsilsesquioxane
- polymerase chain reaction (PCR) and resveratrol
- polymerase chain reaction (PCR) and rheumatoid arthritis (RA)
- polymerase chain reaction (PCR) and synovial fluid
- polymerase chain reaction (PCR) and systemic lupus erythematosus (SLE)
- polymerase chain reaction (PCR) and test
- polymorphism
- polymorphism and genetics
- polymorphism and population studies
- polymorphism and prognostic factors
- polymorphism and proteomics
- polymorphism and psoriasis
- polymorphism and pulmonary complications
- polymorphism and race/ethnicity
- polymorphism and remission
- polymorphism and rheumatoid arthritis
- polymorphism and rheumatoid arthritis (RA)
- polymorphism and spondylarthropathy
- polymorphism and systemic lupus erythematosus (SLE)
- polymorphism and systemic sclerosis
- polymorphism and temporal arteritis
- polymorphism and transcription factor
- polymorphism and uric acid
- polymorphism and uveitis
- Polymorphism and vasculitis
- polymyalgia rheumatica
- Polymyalgia Rheumatica (PMR)
- polymyalgia rheumatica and Diagnostic Tests
- polymyalgia rheumatica and environmental factors
- polymyalgia rheumatica and leukocytes
- polymyalgia rheumatica and methotrexate (MTX)
- polymyalgia rheumatica and population studies
- polymyalgia rheumatica and positron emission tomography (PET)
- polymyalgia rheumatica and prednisolone
- Polymyalgia rheumatica and prognostic factors
- polymyalgia rheumatica and registries
- polymyalgia rheumatica and regulatory cells
- polymyalgia rheumatica and remission
- polymyalgia rheumatica and rheumatoid arthritis (RA)
- polymyalgia rheumatica and risk assessment
- polymyalgia rheumatica and tocilizumab
- polymyalgia rheumatica and treatment
- polymyalgia rheumatica and treatment options
- polymyalgia rheumatica and ultrasonography
- Polymyalgia rheumatica and ultrasound
- polymyalgia rheumatica and vasculitis
- Polymyalgia rhuematica
- polymyalgia rhuematica and prognostic factors
- polymyositis
- polymyositis and polymyositis/dermatomyositis (PM/DM)
- polymyositis and positron emission tomography (PET)
- polymyositis and prognostic factors
- polymyositis and registry
- polymyositis and rehabilitation
- polymyositis and risk assessment
- polymyositis and rituximab
- polymyositis and safety
- polymyositis and signal transduction
- polymyositis and Sjogren's syndrome
- polymyositis and systemic sclerosis
- polymyositis and therapeutic targeting
- polymyositis and ultrasonography
- Polymyositis/dermatomyositis (PM/DM)
- polymyositis/dermatomyositis (PM/DM) and Idiopathic Inflammatory Myopathies (IIM)
- polymyositis/dermatomyositis (PM/DM) and interstitial lung disease